Medications

Upadacitinib beats placebo for psoriatic arthritis

For patients with psoriatic arthritis, upadacitinib at a dose of 15 mg or 30 mg once daily is more effective than placebo, according to a study published in the April 1 issue of the New England Journal of Medicine.

Oncology & Cancer

High-risk clinic for melanoma surveillance is scalable

(HealthDay)—A structured surveillance program for high-risk melanoma patients can be scaled and successfully replicated even in a primary care skin cancer clinic, according to a study published online March 17 in JAMA Dermatology.

Diseases, Conditions, Syndromes

Decline in kidney function faster after COVID-19-related AKI

(HealthDay)—For patients with in-hospital acute kidney injury (AKI), those with COVID-19-associated AKI have a greater rate of decrease in the estimated glomerular filtration rate (eGFR) after discharge, according to a ...

Oncology & Cancer

Tirbanibulin superior to placebo for actinic keratosis

(HealthDay)—Tirbanibulin is superior to vehicle at two months for the treatment of actinic keratosis, but almost half of patients who had a complete response experienced recurrence of lesions at one year, according to a ...

Medications

Rimegepant bests placebo for preventing migraine

(HealthDay)—Taken every other day, rimegepant demonstrates efficacy for the preventive treatment of migraine, according to a study published online Dec. 15 in The Lancet.

Diseases, Conditions, Syndromes

U.S. nephrology trainees doubt skill in home hemodialysis

(HealthDay)—U.S. nephrology trainees report moderate and low confidence for peritoneal dialysis (PD) and home hemodialysis (HHD), respectively, according to a study published online Nov. 16 in the American Journal of Kidney ...

Oncology & Cancer

Darolutamide boosts survival in nonmetastatic prostate cancer

(HealthDay)—For men with nonmetastatic, castration-resistant prostate cancer, the risk for death is significantly lower for those receiving darolutamide versus placebo, according to a study published in the Sept. 10 issue ...

page 1 from 30